Primary immunodeficiency diseases encompass a heterogeneous group of inherited disorders affecting humoral immunity (B cells, antibody production), cellular immunity (T cells), complement, phagocytes, and innate immunity. Stem-cell research investigates whether fetal stem cells and placental mesenchymal stem cells can regenerate lymphoid tissue, promote T-cell and B-cell development within thymic or splenic niches, enhance phagocytic function, and restore immunological tolerance. With 91 registered trials and 13 currently recruiting, the biological rationale targets immune reconstitution through direct progenitor support and paracrine enhancement of developmental microenvironments. Early clinical data suggest potential for improving T-cell counts and function, enhancing antibody responses, reducing infection burden, and improving outcomes in severe combined immunodeficiency and other forms.
Primary immunodeficiency trials represent a substantial evidence base reflecting disease severity and unmet medical need. Thirteen actively recruiting trials indicate ongoing clinical momentum. Published studies document improvements in T-cell counts, restored T-cell proliferation and cytokine production, enhanced antibody responses to vaccination, and reduced infection frequency in responsive cohorts following stem-cell infusion. Several trials in severe combined immunodeficiency showed establishment of T-cell reconstitution permitting reduced dependence on antimicrobial prophylaxis. However, study heterogeneity — varying immunodeficiency types, disease severity, prior treatments — limits generalisation. Long-term immune stability beyond 24 months remains incompletely characterised. Hematopoietic stem-cell transplantation remains the gold standard for select immunodeficiencies; MSC role is emerging as complementary or supportive.
Primary immunodeficiency stem-cell treatment costs typically range €4,000–8,000 per infusion, reflecting the complexity of immunological assessment and monitoring. Fetal stem cells, when used, incur higher sourcing and manufacturing costs than placental MSCs, potentially exceeding €8,000 per cycle. Repeat infusions are common; multi-cycle protocols may total €15,000–25,000. Extensive immunological testing — T-cell subset enumeration, T-cell proliferation assays, antibody titers, vaccine responses — adds €1,500–3,000 to each cycle. Hospital-based immunology programmes typically charge €4,500–7,000; private boutique immune-therapy centres may exceed €8,000. European centres (Germany, Spain, Italy, Austria) generally offer more structured pricing than boutique clinics.
Cell therapy for Primary Immunodeficiency is offered as an individualised, physician-led programme. In the EU and US it is regulated as an advanced therapy rather than an approved 'cure' for this condition — it is currently approved (blood/immune only). That status is exactly why EU GMP oversight, characterised cells and honest evidence matter.
Most protocols involve one treatment visit with one or more infusions over a few days; some patients return for a second cycle. The exact plan — cell type, dose and route — is set only after a clinician reviews your records.
Eligibility depends on condition stage, age and overall health. A clinic should review your records before recommending anything and tell you honestly if you are not a good candidate. Our candidacy self-check gives an indicative read in 60 seconds.
An indicative Primary Immunodeficiency programme is €3,000–€8,000 for treatment (it varies by procedure). Add travel and hotel with our calculator for your true all-in cost — typically a fraction of US, UK or German pricing.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
← Back to Primary Immunodeficiency overview · Primary Immunodeficiency cost →
Medicina regenerativa certificada GMP en el corazón de la UE — desde 3.000–8.000 €, una fracción de los precios de EE. UU. o Alemania. Protocolos personalizados para pacientes de más de 50 países.
Evaluación médica gratuita